Recordati Industria Chimica e Farmaceutica

Board/Management Information • Apr 4, 2020

RECORDATI: NOTICE PURSUANT TO ART. 144-OCTIES, PARAGRAPH 2 OF ISSUERS' REGULATIONS

Milan, 4th April 2020 - Pursuant to art. 144-octies, paragraph 2 of Consob's Regulation 11971/1999 as amended from time to time (the "Issuers' Regulations") RECORDATI S.p.A. informs that, as of today, the only list which has been filed with reference to the appointment of the Board of Statutory Auditors for the period 2020-2022 in the agenda of the Shareholders' General Meeting of 29th April 2020, single call, is the one presented by the majority shareholder Fimei S.p.A..

Therefore, pursuant to art. 144-sexies, paragraph 5, of the aforementioned Issuers Regulations and also pursuant to the Company's By-laws, the deadline for submission of further lists for the appointment of the Company's Board of Statutory Auditors is extended to 7 th April 2020, at 6pm, and the minimum threshold for the submission of lists, fixed at 1% of the Company's share capital having voting rights, is reduced by half, i.e. to 0,5% of the share capital.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

For further information:

Recordati website: www.recordati.com

Investor Relations Media Relations Marianne Tatschke Studio Noris Morano (39)0248787393 (39)0276004736, (39)0276004745

e-mail: investorelations@recordati.it e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale VIA M. CIVITALI, 1 20148 MILANO, ITALIA TEL. (39) 0248787.1 FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v. REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150 CODICE FISCALE/P. IVA 00748210150 R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.àr.l